secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023842
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q3 net loss $77M; cash $537M; Ph3 trials on track for 2023 readouts
--------------------------------------------------------------------------------

- Net loss of $77.0M ($1.47/sh) vs $67.5M ($1.30) in Q3 2021; increase driven by stock-based compensation.
- Cash, cash equivalents and marketable securities of $537.4M; includes $2.5M unrealized loss from interest rates.
- R&D expenses $61.7M (up from $56.0M) and G&A $17.8M (up from $11.5M) both primarily due to non-cash stock comp.
- Four Phase 3 trials (GLEAM/GLIMMER DME, DAYLIGHT wet AMD, GLOW NPDR) expected to report topline data in 2023.
- KSI-501 IND filing on track for Q4 2022; Phase 1 study expected to begin early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022023842/0000950170-22-023842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022023842/kod-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer